Ontology highlight
ABSTRACT:
SUBMITTER: Owen DH
PROVIDER: S-EPMC6673655 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
Owen Dwight H DH Konda Bhavana B Sipos Jennifer J Liu Tom T Webb Amy A Ringel Matthew D MD Timmers Cynthia D CD Shah Manisha H MH
Journal of the National Comprehensive Cancer Network : JNCCN 20190501 5
BRAF V600E mutations occur in approximately 40% of all patients with papillary thyroid cancer (PTC) and are associated with a worse prognosis in population studies. Treatment with single-agent BRAF inhibitors can result in nondurable partial responses (PRs) in clinical trials, but resistance inevitably develops. The mechanisms of resistance are not completely understood, but in non-thyroid tumors harboring BRAF V600E mutations, resistance has been ascribed to concurrent or acquired mutations in ...[more]